Posted by Michael Wonder on 27 Sep 2016
Zinbryta approved by TGA
27 September 2016 - The TGA has approved Biogen's Zinbryta.
The TGA approved daclizumab on 22 September 2016 for the treatment of relapsing forms of multiple sclerosis to delay the progression of physical disability and to reduce the frequency of relapse.
A submission to list daclizumab on the Pharmaceutical Benefits Scheme was deferred by the PBAC in early July.
